Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$24.10 - $62.53
Next Earnings Date
May 08 2025
Next Earnings Date
May 08 2025
Latest price
Market Cap | $3.01B |
EV | $1.71B |
Shares Outstanding | 95.50M |
Beta | 0.37 |
Analyst Rating | BUY |
Analyst Target Price | $75.36 |
P/E 2025E | - |
P/Revenue 2025E | - |
Revenue | -1.20% |
EPS | -9.60% |
Operating Cash Flow | -36.60% |
Free Cash Flow | -37.20% |
Revenue | 466.70% |
EPS | -0.40% |
Operating Cash Flow | -13.70% |
Free Cash Flow | -12.90% |
Gross Margin 2025E | 92.67% |
Net Profit Margin 2025E | -6569.18% |
ROE 2025E | -29.53% |
ROCE 2024 | -32.02% |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Crinetics Pharmaceuticals, Inc.
CRNX
Sector
Healthcare
Industry
Biotechnology
CEO
Struthers, R.
Employees
437
Website
www.crinetics.comIPO Date
2018-07-18
Headquarters
6055 Lusk Boulevard, San Diego, California, 92121, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved